<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Zevra Therapeutics Inc. — News on 6ix</title>
<link>https://6ix.com/company/zevra-therapeutics-inc</link>
<description>Latest news and press releases for Zevra Therapeutics Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/zevra-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835dd7078dffbe2df124baf.webp</url>
<title>Zevra Therapeutics Inc.</title>
<link>https://6ix.com/company/zevra-therapeutics-inc</link>
</image>
<item>
<title>Zevra Therapeutics Announces Details for Q1 2026 Financial Results Call</title>
<link>https://6ix.com/company/zevra-therapeutics-inc/news/zevra-therapeutics-announces-details-for-q1-2026-financial-results-call-5</link>
<guid isPermaLink="true">https://6ix.com/company/zevra-therapeutics-inc/news/zevra-therapeutics-announces-details-for-q1-2026-financial-results-call-5</guid>
<pubDate>Wed, 22 Apr 2026 04:00:00 GMT</pubDate>
<description>BOSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing</description>
</item>
<item>
<title>Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/zevra-therapeutics-inc/news/zevra-therapeutics-reports-inducement-grant-to-new-chief-financial-officer-under-nasdaq-listing-rule-5635c4</link>
<guid isPermaLink="true">https://6ix.com/company/zevra-therapeutics-inc/news/zevra-therapeutics-reports-inducement-grant-to-new-chief-financial-officer-under-nasdaq-listing-rule-5635c4</guid>
<pubDate>Fri, 20 Mar 2026 04:00:00 GMT</pubDate>
<description>BOSTON, March 20, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing</description>
</item>
<item>
<title>Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million</title>
<link>https://6ix.com/company/zevra-therapeutics-inc/news/zevra-therapeutics-sells-sdx-portfolio-to-commave-therapeutics-for-dollar50-million</link>
<guid isPermaLink="true">https://6ix.com/company/zevra-therapeutics-inc/news/zevra-therapeutics-sells-sdx-portfolio-to-commave-therapeutics-for-dollar50-million</guid>
<pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
<description>Companies Resolve Lawsuit in Delaware BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a</description>
</item>
<item>
<title>GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C</title>
<link>https://6ix.com/company/zevra-therapeutics-inc/news/genedx-to-launch-genetic-testing-program-with-zevra-therapeutics-to-support-patients-with-suspected-niemann-pick-disease-type-c-20</link>
<guid isPermaLink="true">https://6ix.com/company/zevra-therapeutics-inc/news/genedx-to-launch-genetic-testing-program-with-zevra-therapeutics-to-support-patients-with-suspected-niemann-pick-disease-type-c-20</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC GAITHERSBURG, Md.--(BUSINESS</description>
</item>
<item>
<title>Zevra Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/zevra-therapeutics-inc/news/zevra-reports-fourth-quarter-and-full-year-2025-financial-results-22</link>
<guid isPermaLink="true">https://6ix.com/company/zevra-therapeutics-inc/news/zevra-reports-fourth-quarter-and-full-year-2025-financial-results-22</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>Q4 net revenue of $34.1 million, representing 31% growth quarter-over-quarter FY 2025 net revenue of $106.5 million, driven by growth in MIPLYFFA® net revenue</description>
</item>
<item>
<title>Zevra Therapeutics Appoints Justin Renz as Chief Financial Officer</title>
<link>https://6ix.com/company/zevra-therapeutics-inc/news/zevra-therapeutics-appoints-justin-renz-as-chief-financial-officer-10</link>
<guid isPermaLink="true">https://6ix.com/company/zevra-therapeutics-inc/news/zevra-therapeutics-appoints-justin-renz-as-chief-financial-officer-10</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>CELEBRATION, Fla., March 05, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on</description>
</item>
<item>
<title>Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call</title>
<link>https://6ix.com/company/zevra-therapeutics-inc/news/zevra-therapeutics-announces-details-for-q4-and-full-year-2025-financial-results-call</link>
<guid isPermaLink="true">https://6ix.com/company/zevra-therapeutics-inc/news/zevra-therapeutics-announces-details-for-q4-and-full-year-2025-financial-results-call</guid>
<pubDate>Mon, 02 Mar 2026 12:30:00 GMT</pubDate>
<description>CELEBRATION, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced it will report corporate and financial results for the fourth quarter and full year 2025 on Monday, March 9, 2026, via a news release after the market close, and will host a conference call/audio webcast at 4:30 p.m. ET that day. A link to the audio webcast will be ac</description>
</item>
<item>
<title>Zevra Therapeutics to Present at the Citizens Life Sciences Conference</title>
<link>https://6ix.com/company/zevra-therapeutics-inc/news/zevra-therapeutics-to-present-at-the-citizens-life-sciences-conference</link>
<guid isPermaLink="true">https://6ix.com/company/zevra-therapeutics-inc/news/zevra-therapeutics-to-present-at-the-citizens-life-sciences-conference</guid>
<pubDate>Wed, 25 Feb 2026 12:30:00 GMT</pubDate>
<description>CELEBRATION, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra’s executive leadership team will present at the Citizens Life Sciences Conference in Miami Beach, FL on Wednesday, March 11, 2026, at 9:00 a.m. ET. Additionally, management will be available for one-on-one meetings with registered conference atten</description>
</item>
<item>
<title>Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™</title>
<link>https://6ix.com/company/zevra-therapeutics-inc/news/zevra-therapeutics-presents-positive-real-123000604</link>
<guid isPermaLink="true">https://6ix.com/company/zevra-therapeutics-inc/news/zevra-therapeutics-presents-positive-real-123000604</guid>
<pubDate>Wed, 04 Feb 2026 12:30:00 GMT</pubDate>
<description>Real-world and clinical trial data underscore long-term safety and effectiveness in pediatric and adult NPC patientsCELEBRATION, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the presentation of four posters highlighting positive new data on MIPLYFFA® (arimoclomol) for the treatment of Niemann-Pick Disease Type C (NPC) at the</description>
</item>
<item>
<title>Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026</title>
<link>https://6ix.com/company/zevra-therapeutics-inc/news/zevra-therapeutics-ring-nasdaq-stock-123000190</link>
<guid isPermaLink="true">https://6ix.com/company/zevra-therapeutics-inc/news/zevra-therapeutics-ring-nasdaq-stock-123000190</guid>
<pubDate>Mon, 02 Feb 2026 12:30:00 GMT</pubDate>
<description>CELEBRATION, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that it has been invited to ring the Nasdaq opening bell on Monday, February 9, 2026. Neil F. McFarlane, Zevra's President and Chief Executive Officer, will deliver opening remarks at 9:24 a.m. followed by the bell ringing at 9:30 a.m. ET, signifying the start of the d</description>
</item>
<item>
<title>Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™</title>
<link>https://6ix.com/company/zevra-therapeutics-inc/news/zevra-therapeutics-present-multiple-analyses-123000616</link>
<guid isPermaLink="true">https://6ix.com/company/zevra-therapeutics-inc/news/zevra-therapeutics-present-multiple-analyses-123000616</guid>
<pubDate>Mon, 26 Jan 2026 12:30:00 GMT</pubDate>
<description>Four abstracts highlighting clinical data and real-world experience with MIPLYFFA accepted for presentation, including an oral presentation by Caroline Hastings, MD Company to host satellite symposium on diagnostic and therapeutic advances in Niemann-Pick disease type C (NPC) CELEBRATION, Fla., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today an</description>
</item>
<item>
<title>Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference</title>
<link>https://6ix.com/company/zevra-therapeutics-inc/news/zevra-therapeutics-present-j-p-123000520</link>
<guid isPermaLink="true">https://6ix.com/company/zevra-therapeutics-inc/news/zevra-therapeutics-present-j-p-123000520</guid>
<pubDate>Thu, 08 Jan 2026 12:30:00 GMT</pubDate>
<description>CELEBRATION, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra’s executive leadership team will present at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco, CA on Thursday, January 15, 2026, at 9:45 a.m. PT. Additionally, management will be available for one-on-one meetings with registered c</description>
</item>
<item>
<title>Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA® for the Treatment of Niemann-Pick Disease Type C (NPC)</title>
<link>https://6ix.com/company/zevra-therapeutics-inc/news/zevra-therapeutics-executes-distribution-agreement-broaden-access-miplyffar-treatment</link>
<guid isPermaLink="true">https://6ix.com/company/zevra-therapeutics-inc/news/zevra-therapeutics-executes-distribution-agreement-broaden-access-miplyffar-treatment</guid>
<pubDate>Mon, 29 Dec 2025 05:00:00 GMT</pubDate>
<description>CELEBRATION, Fla., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on</description>
</item>
<item>
<title>Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/zevra-therapeutics-inc/news/zevra-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-0</link>
<guid isPermaLink="true">https://6ix.com/company/zevra-therapeutics-inc/news/zevra-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-0</guid>
<pubDate>Fri, 12 Dec 2025 05:00:00 GMT</pubDate>
<description>CELEBRATION, Fla., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on</description>
</item>
<item>
<title>Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD</title>
<link>https://6ix.com/company/zevra-therapeutics-inc/news/zevra-therapeutics-inc-appoints-alicia-secor-board-directors-announces-retirement</link>
<guid isPermaLink="true">https://6ix.com/company/zevra-therapeutics-inc/news/zevra-therapeutics-inc-appoints-alicia-secor-board-directors-announces-retirement</guid>
<pubDate>Tue, 02 Dec 2025 05:00:00 GMT</pubDate>
<description>CELEBRATION, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on</description>
</item>
<item>
<title>Zevra Therapeutics, Inc. Announces CFO Transition</title>
<link>https://6ix.com/company/zevra-therapeutics-inc/news/zevra-therapeutics-inc-announces-cfo-transition-2025-11-20</link>
<guid isPermaLink="true">https://6ix.com/company/zevra-therapeutics-inc/news/zevra-therapeutics-inc-announces-cfo-transition-2025-11-20</guid>
<pubDate>Thu, 20 Nov 2025 05:00:00 GMT</pubDate>
<description>CELEBRATION, Fla., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a commercial-stage company focused on</description>
</item>
<item>
<title>Zevra Reports Third Quarter 2025 Financial Results and Corporate Update</title>
<link>https://6ix.com/company/zevra-therapeutics-inc/news/zevra-reports-third-quarter-2025-financial-results-and-corporate-update-2025-11-05</link>
<guid isPermaLink="true">https://6ix.com/company/zevra-therapeutics-inc/news/zevra-reports-third-quarter-2025-financial-results-and-corporate-update-2025-11-05</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>2025 EPS of $(0.01) Q3 2025 net revenue of $26.1 million, driven by MIPLYFFA® net revenue of $22.4 million Company to host conference call and webcast TODAY,</description>
</item>
<item>
<title>Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference</title>
<link>https://6ix.com/company/zevra-therapeutics-inc/news/zevra-therapeutics-participate-guggenheim-healthcare-innovation-conference-2025-10-29</link>
<guid isPermaLink="true">https://6ix.com/company/zevra-therapeutics-inc/news/zevra-therapeutics-participate-guggenheim-healthcare-innovation-conference-2025-10-29</guid>
<pubDate>Wed, 29 Oct 2025 04:00:00 GMT</pubDate>
<description>CELEBRATION, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on</description>
</item>
<item>
<title>Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call</title>
<link>https://6ix.com/company/zevra-therapeutics-inc/news/zevra-therapeutics-announces-details-q3-2025-financial-results-call-2025-10-27</link>
<guid isPermaLink="true">https://6ix.com/company/zevra-therapeutics-inc/news/zevra-therapeutics-announces-details-q3-2025-financial-results-call-2025-10-27</guid>
<pubDate>Mon, 27 Oct 2025 04:00:00 GMT</pubDate>
<description>- Company will host conference call at 4:30 p.m. ET on Wednesday, November 5, 2025 CELEBRATION, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics,</description>
</item>
<item>
<title>Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium phenylbutyrate)</title>
<link>https://6ix.com/company/zevra-therapeutics-inc/news/zevra-therapeutics-announces-upcoming-oral-113000236</link>
<guid isPermaLink="true">https://6ix.com/company/zevra-therapeutics-inc/news/zevra-therapeutics-announces-upcoming-oral-113000236</guid>
<pubDate>Thu, 18 Sep 2025 11:30:00 GMT</pubDate>
<description>MIPLYFFA, the only therapy for Niemann-Pick disease type C (NPC) shown to stop disease progression at 12 months, has been administered to more than 270 patients, representing the largest data set of NPC clinical trial patients OLPRUVA offers the established efficacy and safety of sodium phenylbutyrate in a novel and convenient formulation for the treatment of certain urea cycle disorders CELEBRATION, Fla., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or th</description>
</item>
</channel>
</rss>